![Receptos Logo](/news-release/logo/255198/0/255198.jpg?lastModified=12%2F10%2F2016%2002%3A00%3A24&size=2)
Receptos to Hold Fourth Quarter and Year End 2013 Financial Results Conference Call and Webcast
February 27, 2014 08:00 ET
|
Receptos, Inc.
SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will...
![Receptos Logo](/news-release/logo/255198/0/255198.jpg?lastModified=12%2F10%2F2016%2002%3A00%3A24&size=2)
Receptos Announces Closing of Underwritten Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
January 14, 2014 09:46 ET
|
Receptos, Inc.
SAN DIEGO, Jan. 14, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
![Receptos Logo](/news-release/logo/255198/0/255198.jpg?lastModified=12%2F10%2F2016%2002%3A00%3A24&size=2)
Receptos Announces Pricing of Underwritten Public Offering of Common Stock
January 08, 2014 21:41 ET
|
Receptos, Inc.
SAN DIEGO, Jan. 8, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
![Receptos Logo](/news-release/logo/255198/0/255198.jpg?lastModified=12%2F10%2F2016%2002%3A00%3A24&size=2)
Receptos Begins Enrollment of Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
January 06, 2014 16:05 ET
|
Receptos, Inc.
– Pivotal Phase 3 Trial is Underway with First Patients Randomized in December 2013 –
– Topline Results of Phase 2 Still Expected in Mid-2014...
![Receptos Logo](/news-release/logo/255198/0/255198.jpg?lastModified=12%2F10%2F2016%2002%3A00%3A24&size=2)
Receptos Announces Proposed Underwritten Public Offering of Common Stock
January 06, 2014 16:05 ET
|
Receptos, Inc.
SAN DIEGO, Jan. 6, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
![Receptos Logo](/news-release/logo/255198/0/255198.jpg?lastModified=12%2F10%2F2016%2002%3A00%3A24&size=2)
Receptos and Ono Pharmaceuticals Expand Collaboration Agreement to Include Transfer of Receptos GPCR Technology Platform
December 10, 2013 16:05 ET
|
Receptos, Inc.
SAN DIEGO, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT) announced today that Ono has elected to amend and expand the existing collaboration agreement between the parties to include...
![Receptos Logo](/news-release/logo/255198/0/255198.jpg?lastModified=12%2F10%2F2016%2002%3A00%3A24&size=2)
Receptos to Initiate Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
December 05, 2013 08:00 ET
|
Receptos, Inc.
– Data from Interim Analysis of Phase 2 Trial Provide Support to Advance Program –
– Interim Data Consistent with RPC1063 Differentiation Profile –...
![Receptos Logo](/news-release/logo/255198/0/255198.jpg?lastModified=12%2F10%2F2016%2002%3A00%3A24&size=2)
Christian Waage Appointed General Counsel of Receptos
November 26, 2013 08:00 ET
|
Receptos, Inc.
SAN DIEGO, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT) announced today that Christian Waage has been appointed Senior Vice President and General Counsel of the Company.
Mr. Waage...
![Receptos Logo](/news-release/logo/255198/0/255198.jpg?lastModified=12%2F10%2F2016%2002%3A00%3A24&size=2)
Receptos to Present at 2013 Credit Suisse Healthcare Conference
November 11, 2013 08:00 ET
|
Receptos, Inc.
SAN DIEGO, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
![Receptos Logo](/news-release/logo/255198/0/255198.jpg?lastModified=12%2F10%2F2016%2002%3A00%3A24&size=2)
Receptos Reports Third Quarter 2013 Financial Results
October 30, 2013 16:22 ET
|
Receptos, Inc.
- Phase 2 trial of RPC1063 in relapsing multiple sclerosis has completed enrollment; interim results to be reviewed in Q4 2013 -
- Phase 2 trial of RPC1063 in ulcerative colitis continues to...